CHB-Induced Immune Zonation Chaos Elicited LXRα-mediated Lipid Metabolism Disorders in Kupffer Cells to Induce Cancer Stem Cell Formation
簡介:
- 作者: Jingqi Shi, Qingyu Li, Jian Li, Jian Bai, Ji Xi, Qi He, Jianglin Zhou, Xuejun Wang, Xiang Song, Xiaoju Li, Xiangpei Yue, Xiaochang Zhang, Zhen Sun, Jiangbo Li, Wen Yang, Yuke Cui, Wenjie Shu, Liang Guo, Shengqi Wang
- 雜志: Advanced Science
- Doi: https://doi.org/10.1002/advs.202510275
- 出版日期: 2025/10/30
摘要
Hepatic intercellular communication is the driving force for the progression of chronic Hepatitis B virus (CHB)-associated hepatopathologies, with the dynamic molecular mechanisms largely unknown. Combining scRNA-seq and spatial transcriptomic analysis, the kinetic landscape of the liver microenvironment across time and space in AAV-HBV mice, which develop from inflammation to ultimately hepatocellular carcinoma is generated. Kupffer cells (KCs), originally resided within the peri-portal area, are persistently recruited to the HBV-enriched peri-central region via increased CXCL9 produced by endothelial cells, facilitating the interaction between KCs and HBV+?hepatocytes to induce LXRα deficiency-mediated lipid metabolism disorders (LMD) in KCs. In turn, KCs with LMD elicited cancer stem cell formation from HBV+?hepatocytes via Stat3 pathway, activated by the chemokine network within the crosstalk. Moreover, miR-155-mediated post-transcriptional regulation and ASGR1-dependent degradation collaboratively regulated LXRα downregulation in KCs. LXRα deficiency in KCs is also detected in the tumor tissues of HBV+?patients compared to that of the normal and tumor-adjacent tissue. Importantly, LXRα upregulation in KCs constrained fibrosis and cancer stem cell formation. For the first time, the role of KC zonation in disease progression has been revealed, highlighting LXRα in KCs as a promising target for the early intervention in the transition from CHB-induced inflammation to cancer.
關于派真
作為一家專注于AAV 技術十余年,深耕基因治療領域的CRO&CDMO,派真生物可提供從載體設計、構建到 AAV、慢病毒和 mRNA 服務的一站式解決方案。憑借深厚的技術實力、卓越的運營管理和高標準的服務交付,我們為全球客戶提供一站式CMC解決方案,包括從早期概念驗證、成藥性評估到IIT、IND及BLA的各個階段。
?
憑借我們獨立知識產權的π-alphaTM 293 細胞AAV高產技術平臺,我們能將AAV產量提高多至10倍,每批次產量可達1×101?vg,以滿足多樣化的商業化和臨床項目需求。此外,我們定制化的mRNA和脂質納米顆粒(LNP)產品及服務覆蓋藥物和疫苗開發的各個階段,從研發到符合GMP的生產,提供端到端的一站式解決方案。